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Liver Transplantation

The Role of Dynamic DNA Methylation in Liver
Transplant Rejection in Children
Mylarappa Ningappa, PhD,1 Xiaojian Shao, PhD,2 Chethan Ashokkumar, PhD,1 Qingyong Xu, PhD,3
Adriana Zeevi, PhD,4 Elin Grundberg, PhD,5 Tomi Pastinen, MD, PhD,5 and Rakesh Sindhi, MD1

Background. Transcriptional regulation of liver transplant (LT) rejection may reveal novel predictive and therapeutic
targets. The purpose of this article is to test the role of differential DNA methylation in children with biopsy-proven acute cellular rejection after LT. Methods. Paired peripheral blood DNA samples were obtained before and after LT from 17 children,
including 4 rejectors (Rs) and 13 nonrejectors (NRs), and assayed with MethylC capture sequencing approach covering 5 million CpGs in immune-cell–specific regulatory elements. Differentially methylated CpGs (DMCs) were identified using generalized linear regression models adjusting for sex and age and merged into differentially methylated regions (DMRs) comprising 3
or more DMCs. Results. Contrasting Rs versus NRs, we identified 2238 DMCs in post-LT and 2620 DMCs in pre-LT samples, which clustered in 216 and 282 DMRs, respectively. DMCs associated with R were enriched in enhancers and depleted
in promoters. Among DMRs, the proportion of hypomethylated DMRs increased from 61/282 (22%) in pre-LT to 103/216
(48%, P < 0.0001) in post-LT samples. The highest-ranked biological processes enriched in post-LT DMCs were antigen
processing and presentation via major histocompatibility complex (MHC) class I, MHC class I complex, and peptide binding
(P < 7.92 × 10−17), respectively. Top-ranked DMRs mapped to genes that mediate B-cell receptor signaling (ADAP1) or regulate several immune cells (ARRB2) (P < 3.75 × 10−08). DMRs in MHC class I genes were enriched for single nucleotide polymorphisms (SNPs), which bind transcription factors, affect gene expression and splicing, or alter peptide-binding amino acid
sequences. Conclusions. Dynamic methylation in distal regulatory regions reveals known transplant-relevant MHCdependent rejection pathways and identifies novel loci for future mechanistic evaluations in pediatric transplant subcohorts.
(Transplantation Direct 2022;8: e1394; doi: 10.1097/TXD.0000000000001394).

INTRODUCTION
Epigenetic changes may be better suited to aid management of liver transplant (LT) rejection in children, who
are at risk for cumulative toxicity of lifelong immunosuppression.1 These changes regulate gene transcription by
affecting the binding of transcription factors (TFs) and
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should therefore precede transcription and its clinical
consequences. In turn, patterns of TF binding or the loci‚
which bind to these factors can reveal the particular mechanism of rejection in a given recipient, and the immunosuppressant best able to target that mechanism. This task
is not fulfilled by currently available diagnostic tests. Cell
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function assays predict rejection-risk and not the appropriate immunosuppressant.2 Molecular diagnostics detect
rejection and its progression using predominantly upregulated genes, which may not be mechanistic.3,4
As a clinically usable epigenetic mechanism, DNA methylation is attractive for several reasons.
Epigenetic regulation turns genes on to allow transcription
or turns off genes to silence them. DNA methylation is a common epigenetic change that causes genes to compact around
histones, thereby silencing gene expression. Hypomethylation
unwinds gene that promote transcription. Epigenetic regulation can also be inferred from chromatin states but requires
complex sample preparation procedures.5
As a test substrate, DNA can be easily acquired from several
sources: blood, biopsy or body fluids. Commercially available
arrays use small quantities of DNA to screen methylation status of nearly a million methylation (CpG) sites genome-wide.6
Early DNA methylation studies have identified differentially
methylated regions (DMRs) near genes encoding cytokines as
well as other genes within interferon and mammalian target
of rapamycin signaling pathways, as being relevant in renal
transplant rejection.7,8 No such work has been performed in
pediatric LT recipients.
We and others have shown that trait-associated and
dynamic epigenetic variants are enriched in distal regulatory
enhancer regions and we further showed that these features
are also seen downstream of the transcription start sites—
both genomic regions being underrepresented on commercially available arrays.5-11 To overcome this limitation, we
implemented the methylC-capture sequencing (MCC-Seq)
approach for customized DNA methylation profiling of millions of CpGs located in regulatory elements known to be
active specifically in immune cells.11,12 Specifically, this immune
cell MCC-Seq panel covers (1) the majority of human gene
promoters, blood-cell-lineage–specific enhancer regions and
methylation footprint regions observed in peripheral blood,12
(2) CpGs from Illumina Human Methylation 450 Bead Chips,
and (3) published autoimmune-related single nucleotide polymorphisms (SNPs) and SNPs in their linkage disequilibrium
regions with r2 > 0.8. Here, we test whether MCC-Seq applied
to pre- and post-LT blood samples obtained in the first 90 d
after LT from 17 children with LT can reveal potential mechanisms of LT rejection for further investigation. Four children
experienced early biopsy-proven acute cellular rejection
(rejectors [Rs]) and 13 did not (nonrejector [NRs]).

MATERIALS AND METHODS
Human Subjects
Archived DNA extracted from blood samples from 17
children with LT was tested under University of Pittsburgh
Institutional Review Board approved study #19030279.
Mean ± SD age of subjects was 6.3 ± 8.2 y and male:female
gender distribution was 6:11. Indications for LT included
primary diagnoses such as biliary atresia in 6, maple syrup
urine disease in 4, urea cycle in 5, Propionic acedimia in 1,
and cystic fibrosis in 1. Four of the 17 children experienced
acute cellular rejection within 90 d of transplant and were
termed rejectors (Rs). Thirteen of the 17 children had no
rejection. DNA samples were collected before and within
the first 90 d after LT. For the 4 rejectors, post-LT samples
were collected at 9.75 ± 10.8 d before the rejection event. All
4 patients experienced steroid-responsive rejection. None

needed antilymphocyte treatment for steroid-resistant rejection. The number of HLA mismatches in Rs and NRs was not
significant (Table S1, SDC, http://links.lww.com/TXD/A466).
MCC-Seq
One µg of DNA was used for whole genome bisulfite sequencing library preparation (KAPA Biosystems, Wilmington, MA),
bisulphite conversion (Epitect Fast DNA Bisulfite Kit [Qiagen]),
and enrichment (12-plex) using the custom probes10,13 according to the Roche NimbleGen SeqCapEpi Enrichment System
protocol (Wilmington, MA). We compared DNA methylation
differences between Rs and NRs using a general linear regression model adjusted for age and sex. Correction of immune
cell proportion was performed with constrained linear projection via the projectMix function of the RefFreeEWAS package
(version 2.2), using a custom panel of 30 455 cell-type–specific
hypomethylated and hypermethylated CpGs.14 The blood reference epigenome profiles include megakaryocyte, neutrophil,
monocyte, B cell, and T cell. Differentially methylated CpGs
(DMCs) were further filtered if the DNA methylation profile
is correlated with any of the estimated blood proportion at
nominal P <0.05. To assess potential regional clustering of significant DMCs, candidate regions surrounding the blood corrected DMCs were expanded for up to 200-bp distance both
upstream and downstream. Within these candidate regions,
all consecutive CpGs with methylation changes in the same
direction and with nominal P <0.01 were merged. Regions
with at least 3 CpGs fulfilling these criteria were considered
DMRs. Gene ontology function enrichment analysis of rejection-associated DMCs was performed using Genomic Regions
Enrichment of Annotations Tool.15

RESULTS
CpGs that Characterize Rejectors are Enriched in
Distal Regions and Hypomethylated After LT
Of the ~2.5 million autosomal CpGs tested in the association analysis, we identified 3357 DMCs including 1894
hypomethylated and 1463 hypermethylated CpGs in post-LT
samples from R compared with NR. The genome-wide distribution of significant CpGs is shown in Figure 1A. Among the
3357 DMCs, 1117 were significantly correlated with blood
cell proportions and were excluded. Among the remaining
2238 DMCs, 1108 were hypermethylated and 1130 were
hypomethylated (Tables 1 and Table S2, SDC, http://links.
lww.com/TXD/A466). To further explore how the DMCs
mapped to regions, we identified DMRs containing clusters of
3 or more DMCs with the same directional change in methylation. Of 216 DMRs that clearly distinguished R and NR
groups, 113 (52%) were hypermethylated and 103 (48%)
were hypomethylated (Figure 1B, Table S3, SDC, http://links.
lww.com/TXD/A466). Examples include intronic regions in
ADAP1 (50 DMCs, chr7:948678-949115, Figure 1C) and
LHX6 (34 DMCs) and the intergenic region near ARRB2
(24 DMCs) (Table S3, SDC, http://links.lww.com/TXD/
A466).16-18 Enrichment analysis of genomic regions revealed
that rejection-associated DMCs and DMRs were enriched in
the distal regulatory regions and depleted in the promoter
regions (Table S3, SDC, http://links.lww.com/TXD/A466).
Next, we identified significant genome-wide DMCs in pre-LT
samples from Rs compared with NRs. After filtering DMCs
(n = 665)‚ which correlated significantly with blood proportions,
2620 DMCs remained‚ of which 1413 were hypermethylated

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 1. Identification of differentially methylated CpGs (DMCs) for LT rejection. (A) Manhattan plot of P values from association analysis to
identify differentially methylated CpGs. (B) Heatmap of DMCs in methylation profiles for all individuals. Phenotype features including sex, age
onset, and LT rejection status are illustrated in the bars on top of the heatmap. (C). DNA methylation pattern at the differentially methylated region
(DMR) for ADAP1 (chr7:948678-949115). This region shows consistent hypermethylation among R (pink) compared with NR (blue) over 50
DMCs. CpGs, methylations; LT, liver transplant; LTNR, liver transplant nonrejector; LTR, liver transplant rejection; NR, nonrejector.

4

Transplantation DIRECT

www.transplantationdirect.com

■ 2022

TABLE 1.

Summary of differentially methylated CpGs and regions

No. CpGs
No. DMCs
No. Hypermethylated DMCs
No. Hypomethylated DMCs
No. DMRs
No. Hypermethylated DMRs
No. Hypomethylated DMRs

Post-LT

Pre-LT

2 544 280
2238
1108
1130
216
113
103

2 545 085
2620
1413
1207
282
221
61

DMC, differentially methylated CpG; DMR, differentially methylated region; LT, liver
transplant.
Counts of DMCs (Tables S2 and S4, SDC, http://links.lww.com/TXD/A466) and
DMRs (Tables S3 and S5, SDC, http://links.lww.com/TXD/A466) in samples
obtained from 4 rejectors compared with those from 13 nonrejectors within 90 d
post LT) and pre LT.

and 1207 were hypomethylated (Table S4, SDC, http://links.
lww.com/TXD/A466). Among these DMCs, we identified
282 DMRs consisting of 221 (78%) hypermethylated and 61

(22%) hypomethylated DMRs (Table S5, SDC, http://links.
lww.com/TXD/A466). Thus, as proportion of all DMRs,
hypomethylated DMRs increased from 61/282 (22%) in preLT to 103/216 (48%, P < 0.0001) in post-LT samples.
Functional Enrichment Analysis Reveals
Mechanisms for Additional Investigation
The genes associated with DMCs located within the DMRs
regions in posttransplant samples were enriched for the biological
processes of antigen processing and presentation of exogenous peptide antigen via major histocompatibility complex (MHC) class I,
(P = 4.4 × 10−21) and cellular component of “MHC protein complex” (P = 1.7 × 10−23) and molecular function of peptide antigen binding (P = 7.9 × 10−17) (Figure 2,
Table S6, SDC, http://links.lww.com/TXD/A466). DMCs in
pretransplant samples were enriched for the top-ranked biological processes of “regulation of thyroid-stimulating hormone
secretion” (P < 3.1 × 10−58) and several developmental and morphogenesis processes. “Antigen processing and presentation of
exogenous peptide antigen via MHC class” ranked 17th among

FIGURE 2. Enrichment in posttransplant samples. Top-ranked 20 gene ontology (GO) bological processes (BP), cellular component (CC)‚ and
molecular function (MF) enriched in R compared with NR in DMCs located within regions of DMRs in posttransplant samples. DMC, differentially
methylated CpG; DMR, differentially methylated region; NR, nonrejector; R, rejector.

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

these processes (P < 9.5 × 10−34) (Figure 3, Table S7, SDC, http://
links.lww.com/TXD/A466). Enriched top-ranked cellular components included “MHC class I protein complex” (P < 9.1 × 10−36),
and top-ranked molecular functions included “thyroid-stimulating hormone receptor activity” (P < 2.6 × 10−55)” and “peptide
antigen binding” (P < 1.8 × 10−30) (Figure 3, Table S7, SDC, http://
links.lww.com/TXD/A466). The top-ranked enriched pathways
among pretransplant DMC were consistent with the developmental nature of liver disease affecting children who present
for transplantation. Liver development is regulated by thyroid
hormones, manifested in the top-ranked pathways of regulation
of thyroid-stimulating hormone secretion P = 4.06E-54 (Table
S7, SDC, http://links.lww.com/TXD/A466).19,20 Liver components like hepatic stellate cells and sinusoidal epithelium originate from the mesoderm, as does the metanephric collecting duct
system, represented by the pathway “regulation of metanephric
nephron tubule epithelial cell differentiation, P = 3.7 × 10−36”
(Table S7, SDC, http://links.lww.com/TXD/A466).21 Enrichment
of DMRs in MHC class I molecules among rejectors was demonstrable in coding sequences of HLA-C and intronic reqions of
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HLA-F in pretransplant samples and the HLA-B promoter
sequence in posttransplant samples.
Public databases reveal that all 3 HLA DMRs (HLA-C,
HLA-F, and HLA-B) contain known single nucleotide polymorphisms, which are known to bind to TFs, alter expression
of the corresponding gene, or affect peptide antigen binding
(SNPs) (Table S8A–C, SDC, http://links.lww.com/TXD/A466,
Figure S1, SDC, http://links.lww.com/TXD/A465). SNPs associated with altered gene expression or expressed quantitative
trait loci are shown in Figure S1, SDC, http://links.lww.com/
TXD/A465. However, the differential methylation between R
versus NR was not associated with the degree of mismatches
between the donor and recipient in traditional pretransplant
HLA typing of HLA-B (mean ± SD 1.5 ± 0.58 versus 1.69 ± 0.48,
P = 0.577, (not significant) and HLA-C alleles (mean ± SD
1 ± 0.82 versus 1.38 ± 0.51, P = 0.42, not significant).

DISCUSSION
Our study shows that rejection after LT in children is associated with differential DNA methylation affecting distal

FIGURE 3. Enrichment in pretransplant samples. Top-ranked 20 gene ontology (GO) bological processes (BP), cellular component (CC), and
molecular function (MF) enriched in R compared with NR in DMCs located within regions of DMRs in pretransplant samples. DMC, differentially
methylated CpG; DMR, differentially methylated region; NR, nonrejector; R, rejector.
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regions of genes, and with 3-fold increase in hypomethylated:
hypermethylated regions (103:113) compared with pretransplant status (61:221; P = 0.0001) (Figure 1B and Table 1).
This is to be expected because dynamic changes in methylation that are induced by disease predominantly affect distal
regions such as enhancers, for which the MCC-seq platform
is especially suited. Differentially methylated loci also reveal
several new directions for future study. First, DMRs containing the highest number of DMCs are present in several loci
that could regulate the rejection alloresponse (Table S3, SDC,
http://links.lww.com/TXD/A466). These loci include ADAP1
(Figure 1C)‚ which participates in B cell receptor signaling17;
ARRB2, which negatively regulates inflammatory responses
of many immune cells including T cell and B cell18; and LHX6
which regulates the development of many cells including lymphoid cells.22 A larger association study and functional experiments are needed to confirm this possibility.
Second, enrichment analyses suggest that posttransplant
rejection may recruit MHC I molecules, which classically
present endogenous antigen, to present exogenous (transplant) antigens.23 Exogenous antigens are usually presented
by MHC class II molecules. This possibility is based on the
emergence of transporter associated with antigen processing
(TAP)–independent antigen processing and presentation of
peptide antigen via MHC class I, as the top-ranked biological process, and MHC class I protein complex and peptide
antigen binding as the top-ranked cellular component and
molecular function, respectively, in posttransplant samples
from rejectors compared with NRs (Figure 2, Table S6, SDC,
http://links.lww.com/TXD/A466). The TAP proteins bind to
the complex between MHC class I molecules and endogenous peptide antigens, aiding transport of this complex
to the cell surface.16 Presentation of exogenous antigen via
MHC class I does not require TAP. Consistent with a shift to
TAP-independent antigen presentation after transplantation,
pretransplant DMCs are enriched for molecular functions
of TAP1- and TAP2-binding and peptide antigen binding,
and the cellular component, MHC class I protein complex.
Pre-LT samples were also enriched for several biological processes related to morphogenesis, for example, pronephric field
specification and nephron morphogenesis, reflecting the contribution of underlying developmental diseases that require
liver transplantation, to the pretransplant blood methylome
(Figure 3, Table S7, SDC, http://links.lww.com/TXD/A466).
Third, these enrichment results suggests that dynamic
methylation could add to the clinical utility of the MHC locus
by predicting transplant rejection. Currently, donor–recipient
mismatches at polymorphic HLA alleles are used to assess histocomatibility. These mismatches lead to donor-specific antiHLA antibodies (DSA), which are increasingly implicated in
late graft loss, and DSA specificity.23-28 Highly polymorphic
HLA genes, for which corresponding proteins show high
expression on the cell surface induce DSA more frequently
(HLA-DR, HLA-DQ, and HLA-B).29-31 Polymorphisms in
HLA-B, which is enriched for DMRs in posttransplant samples from rejectors are also associated with TAP-independent
MHC class I antigen processing and presentation of exogenous antigens and have been used to explain CD8-mediated
cytotoxicity in a variety of autoimmune diseases.32-34 TAPindependent class I antigen presentation after LT may also
explain why alloresponsive CD8-memory cells are also being
used clinically to predict acute LT rejection in children.2
Others HLA genes are less polymorphic and have low surface

expression because of predominantly intracellular location,
which is influenced in part by binding to TAP. These genes are
either associated with a low incidence of DSA (HLA-C), or
have no known function (HLA-F). HLA-C is largely intracellular where it remains bound to TAP.29 HLA-F expression is
restricted to the B cell lineage in the resting state, also partly
influenced by binding to TAP.30 DMRs in HLA-C and HLA-F
are enriched in pretransplant samples from rejectors in our
study.
Finally, public databases reveal how sequence variants in
DMR of the HLA genes may affect the rejection alloresponse
via dynamic methylation, highlighting a complexity that has
yet to be understood fully. The expression of MHC molecules
is regulated by binding of TFs to regulatory elements.35-37 This
binding is influenced by polymorphisms at TF binding sites.
An example is the CCCTC binding TF, CTCF, which regulates
the expression of several MHC genes.38-39 We have previously
shown the effect of altered methylation on CTCF-mediated
expression of HLA-DOA, a B cell–specific MHC gene, and
the relationship of SNPs in these regulatory loci to B cell presentation of donor antigen during LT rejection in children.40,41
Consistent with these reports, each DMR in the HLA-B, -C,
and -F genes contains known SNPs, which either bind TFs,
bring about amino acid changes in the peptide-biding regions
of corresponding MHC molecules, or may explain cell–cell
interactions such as those between HLA-F and natural killer
cells, which underlie immunity and tolerance (Table S8, SDC,
http://links.lww.com/TXD/A466). For example, the SNPs
rs2076177 and rs1736924 in the DMR of HLA-F in rejectors are, respectively, associated with enhanced and decreased
expression and splicing in public databases (Figure S1, SDC,
http://links.lww.com/TXD/A465). Thus, the study of dynamic
DNA methylation can reveal potential causal links between
genetic variation and transcriptional regulation, and facilitate
preventive intervention by predicting rejection.
In conclusion, and consistent with several previous studies in nontransplant settings, our study localizes dynamic
DNA methylation associated with LT rejection in children, to
mostly nonpromoter distal regulatory regions. The emergence
of the well-known transplant-relevant MHC-dependent antigen presentation as an enriched pathway, and of associated
MHC class I-dependent mechanisms among rejectors in this
exploratory cohort adds to the validity of DNA methylation as
an investigative tool. Given that this enrichment is associated
with novel but plausible differentially methylated regulatory
loci, DNA methylation analysis can identify novel mechanisms and hypotheses for further investigation in the rare
pediatric LT subcohort of transplant recipients. Limitations to
be addressed in follow-up studies include a larger sample size,
and evaluation of methylation status of DNA derived from
intragraft immune cells in addition to DNA derived from
unfractionated peripheral blood leukocytes.
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